Zach Jonasson PhD
Managing General Partner
Dr. Jonasson is a Managing General Partner and co-founder of PVP. He leads PVP’s investment strategy in life sciences and healthcare verticals. Dr. Jonasson brings over 25 years of experience in venture capital, entrepreneurship, and start-up operations. He was the co-founder and initial CEO of ReForm Biologics, a start-up developing next generation formulations technologies for biotherapeutics, and a cofounder of Crop Enhancement, a start-up developing sustainable chemicals for pre- and post-harvest crop protection. Previously, he was a General Partner and Kauffman Fellow at Seaflower Ventures. Dr. Jonasson’s current and prior investments include Serenex (acquired by Pfizer), MetaWorks (acquired by UBC), Valeritas (ZEAL), Lucira Health (LHDX), L7 Informatics, AbSci, Sentinel Monitoring Systems, TelMed IQ (acquired by PerfectServe), Dark Vision (acquired by Koch Industries) and Totient. Earlier in his career, while still a doctoral student, Dr. Jonasson was part of the initial five person team at RCM (acquired by Towers Perrin).
Dr. Jonasson earned a BS from Georgetown University’s Honor Program and an AM and PhD from Harvard University, where he was a Sackler Scholar pursuing research into the neurobiology underlying learning and memory processes. While a graduate student, he taught market research methods at Harvard Business School. In addition to his investment and board roles at PVP, Dr. Jonasson serves on the board of the Oregon Translational Research and Development Institute (OTRADI), on the Commercialization Council of the Oregon Nanoscience and Microtechnologies Institute (ONAMI), and on the Advisory Board of the Life Sciences Institute at the University of British Columbia. Dr. Jonasson is based in Seattle where he enjoys hiking and kayaking with his wife and two children.